Saliva Fatigue Biomarker Index As a Marker for Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in a Community Based Sample.
Jason, Leonard A, Kalns, John, Richarte, Alicia et al. · Fatigue : biomedicine, health & behavior · 2021 · DOI
Quick Summary
Researchers tested whether a simple saliva test could help diagnose severe ME/CFS in children and teens. They measured two protein fragments in saliva from young people with ME/CFS and compared them to healthy controls. The study found that this 'Fatigue Biomarker Index' showed significant differences between those with severe ME/CFS and healthy youth, suggesting it might one day be a useful objective test to help doctors diagnose the condition.
Why It Matters
ME/CFS currently lacks objective diagnostic tests, forcing reliance on clinical symptoms and exclusion of other diagnoses. An objective biomarker could accelerate diagnosis, reduce patient suffering from delayed recognition, and improve access to appropriate treatment. If validated, a salivary test would be non-invasive and scalable, making it particularly valuable for pediatric populations and underserved communities.
Observed Findings
Significant differences in salivary Fatigue Biomarker Index concentrations were found between severe ME/CFS cases and matched healthy controls.
The FBI showed greater discriminatory power for severe ME/CFS compared to milder ME/CFS cases.
The study enrolled 59 youth with ME/CFS and 39 matched controls from a diverse, community-based random sample of over 10,000 participants.
Physician diagnosis was based on established ME/CFS case definitions following comprehensive medical and psychiatric evaluations.
Inferred Conclusions
A salivary peptide ratio (FBI) may serve as an objective biomarker capable of distinguishing severe ME/CFS from health controls.
If validated in other populations, the FBI could aid clinical diagnosis and reduce diagnostic delays in ME/CFS.
This biomarker warrants further investigation as a potential non-invasive, scalable diagnostic tool for ME/CFS.
Remaining Questions
Does the FBI predict ME/CFS severity longitudinally, or does it change with disease course and treatment?
Can the FBI distinguish ME/CFS from other conditions causing chronic fatigue, such as autoimmune diseases, depression, or other post-viral syndromes?
What biological processes do these two peptide fragments reflect, and how do they relate to ME/CFS pathophysiology?
What This Study Does Not Prove
This study does not prove the FBI causes ME/CFS or explain the biological mechanism behind the findings. The modest sample size and case-control design cannot establish whether the biomarker is present before symptom onset or whether it persists after recovery. Findings must be replicated in independent populations before the test can be considered clinically useful.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Phenotype:SeverePediatric
Method Flag:Small SampleExploratory OnlyStrong PhenotypingSevere ME Included